Avalo Therapeutics Inc expected to post a loss of $1.77 a share - Earnings Preview

Avalo Therapeutics

29/07/2022 14:13

* Avalo Therapeutics Inc  AVTX.OQ   AVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 1
(estimated). 
    * The Rockville Maryland-based  company is expected to
report  a
76.4% decrease in revenue to $791 thousand from $3.36 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Avalo Therapeutics
Inc is
for a loss of $1.77 per share. For the same quarter last year,
the company reported a loss of $2.16 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $40.5​, above​ its last closing price
of $3.60. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -1.55       -1.60      -2.40     Missed  -50
 Dec. 31 2022  -1.75       -1.90      -1.92     Missed  -1.3
 Sep. 30 2021  -2.19       -2.16      -2.04     Beat    5.6​
 Jun. 30 2021  -2.09       -2.04      -2.16     Missed  -5.9
 ​​Mar.        -2.47       -2.32      -3.84     Missed  -65.5
 31 2021                                                
 Dec. 31 2020  -1.80       -1.80      -2.16     Missed  -20​
 Sep. 30 2020  -1.44       -1.14      -2.04     Missed  -78.9
 Jun. 30 2020  -1.20       -1.26      -2.28     Missed  -81
 This summary was machine generated July 29 at 13:13 GMT.  All
figures in US dollars  unless otherwise stated